FDA Approves VTAMA for the Topical Treatment of Plaque Psoriasis

Dermavant Sciences has received FDA approval for its novel topical treatment, VTAMA, for adults with plaque psoriasis. The cream contains tapinarof, which has been found effective in treating the chronic skin condition. Over 1,800 patients from diverse backgrounds participated in the clinical trial, overcoming challenges with patient diversity. The approval is significant in providing patients with a new option for managing psoriasis and advancing medicine through extensive research and development.

DelRicht’s Role and Perspective

DelRicht Research, a clinical research organization, played a vital role in the clinical trial, with principal investigators Dr. Ira Thorla and Dr. Sarah Jackson. Both attended LSU Health, New Orleans. “We are proud to have been part of the clinical trial team for VTAMA and to have contributed to the development of this novel treatment option,” said Marshall Morris, Partner at DelRicht Research.

“We are proud to have been part of the clinical trial team for VTAMA and to have contributed to the development of this novel treatment option.”

— Marshall Morris, Partner at DelRicht Research

Why This Approval Matters

The approval of VTAMA marks a significant milestone in the treatment of psoriasis and highlights the importance of collaboration and diversity in research. “We are thrilled with the FDA’s approval of VTAMA, which we believe represents a significant advance in the treatment of plaque psoriasis,” said Todd Zavodnick, CEO of Dermavant Sciences. “We look forward to making VTAMA available to patients in the near future.”

“We are thrilled with the FDA’s approval of VTAMA, which we believe represents a significant advance in the treatment of plaque psoriasis.”

— Todd Zavodnick, CEO of Dermavant Sciences

Meeting Unmet Needs in the Psoriasis Community

Psoriasis affects approximately 8 million people in the United States, and Dermavant’s approval provides a new treatment option for patients who have not responded to traditional therapies. The company plans to launch VTAMA in the second half of 2022, pending final pricing and insurance coverage decisions.

In addition to the clinical trial’s success, Dermavant Sciences is also conducting further research on tapinarof’s potential to treat other inflammatory skin conditions, such as atopic dermatitis and alopecia areata.

“The approval of VTAMA represents an important milestone for Dermavant Sciences and for patients with plaque psoriasis,” said Zavodnick. “We remain committed to advancing the science of dermatology and bringing innovative treatments to patients in need.”

Advancing Plaque Psoriasis Treatment Through Research

Overall, the approval of VTAMA demonstrates the significance of collaboration between pharmaceutical companies and clinical research organizations in advancing medicine. It also highlights the importance of diversity in clinical trials, ensuring that medications are effective across a wide range of patient populations. With the approval of VTAMA, patients with plaque psoriasis have a new treatment option, and the potential for further research may provide relief for those with other skin conditions.